Medapia

Entacapone, the active ingredient in Medapia, is a catechol‑O‑methyltransferase (COMT) inhibitor presented as an oral tablet (strength not specified) for oral use. It is used as adjunct therapy to enhance levodopa efficacy in patients with Parkinson’s disease.

GNH USA supplies Medapia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Entacapone is indicated as an adjunct therapy in the management of Parkinson’s disease, where it enhances levodopa availability.

- Parkinson’s disease (as adjunct to levodopa/carbidopa therapy): prolongs levodopa half‑life and improves motor symptom control.

Entacapone may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Diarrhea - Darkened urine - Dizziness - Insomnia - Constipation

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe allergic reactions (rash, angioedema, anaphylaxis) - Neutropenia or leukopenia - Exacerbation of dyskinesia - Hypotension - Mood changes or depression

When prescribing Entacapone, clinicians should consider several safety measures.

- Liver monitoring: assess hepatic function before initiation and periodically during therapy. - Dyskinesia risk: evaluate for worsening levodopa‑induced dyskinesia and adjust levodopa dose if needed. - Renal impairment: use caution in patients with severe renal dysfunction. - Concomitant COMT inhibitors: avoid co‑administration with other COMT inhibitors such as tolcapone. - Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Entacapone can modify the effects of several co‑administered medicines.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Tolcapone: additive COMT inhibition may increase toxicity. - Certain antihypertensives (e.g., alpha‑blockers): may potentiate hypotensive effects.

Moderate Interactions (Monitor Closely): - Levodopa/carbidopa: dose adjustments often required to manage dyskinesia. - Anticholinergic agents: may increase anticholinergic burden. - SSRIs and SNRIs: monitor for serotonin syndrome when combined with MAO‑B inhibitors.